Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Sarcoma 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms, Neuroepithelial 1Neoplasms 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hodgkin Disease 1Gliosarcoma 1Glioma 1Glioblastoma 1Esophageal Neoplasms 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Desmoplastic Small Round Cell Tumor 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Peripheral Blood Stem Cell Transplantation 6Cyclophosphamide 6fludarabine phosphate 5Nivolumab 5Mycophenolic Acid 5Carboplatin 5Whole-Body Irradiation 4Radiotherapy 4Filgrastim 4Cyclosporine 4Gemcitabine 3Cisplatin 3Busulfan 3Antilymphocyte Serum 3cabozantinib 2cabazitaxel 2Voriconazole 2Thiotepa 2Therapeutics 2Standard of Care 2Sirolimus 2Polymerase Chain Reaction 2Mitomycin 2Methylprednisolone 2Methotrexate 2Melphalan 2Itraconazole 2Immunoglobulin G 2Goserelin 2Flow Cytometry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × CLR1404 × Genitourinary × Clear all
NCT01495663 2015-02-26

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Cellectar Biosciences, Inc.

Phase 1 Completed
12 enrolled
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡